Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Avanafil (TA1790) is a selective inhibitor of phosphodiesterase type 5 (PDE5) and is used as therapy of erectile dysfunction.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | In stock | $ 47.00 | |
50 mg | In stock | $ 58.00 | |
100 mg | In stock | $ 94.00 | |
200 mg | In stock | $ 113.00 | |
500 mg | In stock | $ 139.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 50.00 |
Description | Avanafil (TA1790) is a selective inhibitor of phosphodiesterase type 5 (PDE5) and is used as therapy of erectile dysfunction. |
Targets&IC50 | PDE5:1 nM |
In vitro | In the corpus cavernosum of rats with Type 2 Diabetes Mellitus (T2DM), the injection of Avanafil (1 μM) has been demonstrated to enhance erectile function. |
Synonyms | TA1790 |
Molecular Weight | 483.95 |
Formula | C23H26ClN7O3 |
CAS No. | 330784-47-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 90 mg/mL (186 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Avanafil 330784-47-9 Metabolism PDE Phosphodiesterase (PDE) bone density TA-1790 Endogenous Metabolite Inhibitor osteoporosis dexamethasone NOS Nitric oxide synthases corpus cavernosum erectile dysfunction inhibit NO Synthase TA 1790 TA1790 inhibitor